effect
vaccin
hepat
c
viru
hcv
major
unmet
need
requir
antigen
elicit
immun
respons
key
conserv
epitop
base
structur
antibodi
target
hcv
envelop
glycoprotein
design
immunogen
modul
structur
dynam
favor
induct
bnab
context
vaccin
design
includ
point
mutat
key
conserv
antigen
site
stabil
conform
well
redesign
immunogen
region
add
new
nglycosyl
site
mask
antibodi
bind
design
experiment
character
bind
panel
human
monoclon
antibodi
hmab
coreceptor
confirm
preserv
epitop
structur
prefer
antigen
profil
select
design
test
immunogen
mice
without
hypervari
region
immunogen
region
associ
viral
escap
one
design
show
improv
polyclon
immun
serum
bind
hcv
pseudoparticl
neutral
isol
associ
antibodi
resist
result
indic
antigen
optim
structurebas
design
envelop
glycoprotein
promis
rout
effect
vaccin
hcv
authorfund
right
reserv
reus
allow
without
permiss
hepat
c
viru
infect
approxim
world
popul
vaccin
current
avail
due
high
variabl
hcv
abil
activ
escap
immun
respons
goal
hcv
vaccin
design
induc
neutral
antibodi
target
conserv
epitop
perform
structurebas
design
sever
epitop
hcv
envelop
glycoprotein
engin
antigen
properti
design
test
vitro
vivo
demonstr
alter
antigen
profil
sever
case
one
design
led
improv
crossneutr
heterolog
virus
repres
proof
concept
ration
engin
hcv
envelop
glycoprotein
use
modul
antigen
optim
vaccin
challeng
viral
target
hepat
c
viru
hcv
infect
major
global
diseas
burden
million
individu
approxim
global
popul
chronic
infect
worldwid
million
new
infect
per
year
chronic
hcv
infect
lead
cirrhosi
hepatocellular
carcinoma
lead
caus
liver
cancer
unit
state
hcv
found
surpass
hiv
infecti
condit
caus
death
develop
directact
antivir
improv
treatment
option
consider
sever
factor
imped
effect
use
antivir
treatment
high
cost
antivir
viral
resist
occurr
reinfect
treatment
cessat
lack
awar
infect
mani
individu
sinc
hcv
infect
consid
silent
epidem
therefor
develop
effect
prevent
vaccin
hcv
necessari
reduc
burden
infect
transmiss
global
elimin
hcv
despit
decad
research
result
sever
hcv
vaccin
candid
test
vivo
clinic
trial
approv
hcv
vaccin
avail
number
barrier
develop
effect
hcv
vaccin
includ
high
mutat
rate
viru
lead
viral
quasispeci
individu
permit
activ
evas
cell
b
cell
respons
escap
antibodi
respons
hcv
includ
mutat
envelop
glycoprotein
observ
vivo
human
mice
studi
chimpanze
model
analysi
viral
isol
human
chronic
infect
also
clearli
demonstr
clinic
trial
monoclon
antibodi
spite
target
conserv
epitop
viral
envelop
fail
elimin
viru
viral
variant
epitop
mutat
emerg
immun
pressur
domin
rebound
viral
popul
treat
individu
number
success
structurebas
vaccin
design
variabl
virus
influenza
hiv
rsv
ration
design
immunogen
optim
present
key
conserv
epitop
mask
site
use
nglycan
stabil
conform
assembl
envelop
glycoprotein
recent
studi
report
use
sever
strategi
context
hcv
glycoprotein
includ
remov
modif
nglycan
improv
epitop
access
remov
hypervari
region
present
key
conserv
epitop
scaffold
howev
studi
rel
limit
compar
virus
term
design
strategi
employ
number
design
test
immunogen
studi
shown
convinc
improv
glycoprotein
design
nativ
glycoprotein
term
neutral
potenc
breadth
possibl
except
hvrdelet
high
molecular
weight
form
glycoprotein
test
guinea
pig
report
gener
character
vivo
immunogen
novel
structurebas
design
hcv
glycoprotein
primari
target
antibodi
respons
hcv
major
vaccin
target
design
focus
antigen
domain
key
region
target
broadli
neutral
antibodi
bnab
resist
viral
escap
well
antigen
domain
target
nonneutr
antibodi
base
intrins
flexibl
neutral
face
includ
antigen
domain
locat
bnab
epitop
domain
identifi
structureauthorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
base
design
substitut
reduc
mobil
region
preferenti
form
bnabbound
conform
also
test
sever
substitut
hyperglycosyl
mask
antigen
domain
locat
uniqu
region
back
layer
determin
fine
epitop
map
repres
approach
appli
mask
epitop
influenza
hiv
glycoprotein
design
test
antigen
use
panel
monoclon
antibodi
mab
select
design
test
individu
combin
vivo
immunogen
assess
immun
sera
reveal
certain
design
yield
improv
serum
bind
recombin
hcv
particl
well
viral
crossneutr
maintain
serum
bind
solubl
glycoprotein
key
epitop
provid
proofofconcept
ration
design
hcv
glycoprotein
lead
improv
immunogen
neutral
breadth
util
two
approach
design
variant
glycoprotein
improv
antigen
immunogen
figur
one
approach
use
previous
report
structur
affin
matur
bnab
bound
epitop
antigen
domain
pdb
code
show
epitop
conform
observ
context
domain
human
monoclon
antibodi
hmab
target
site
analysi
epitop
structur
potenti
prolin
residu
substitut
stabil
hmabbound
conform
identifi
sever
candid
site
figur
tabl
select
one
substitut
adjac
core
contact
residu
domain
locat
aa
subsequ
experiment
character
due
posit
region
secondari
structur
locat
residu
make
key
antibodi
contact
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
domain
antibodi
complex
structur
also
repres
distinct
region
epitop
substitut
previous
describ
test
anoth
design
approach
hyperglycosyl
util
mask
antigen
domain
immunogen
region
back
layer
associ
nonneutr
antibodi
antibodi
bind
determin
map
region
includ
hmab
exhibit
limit
weak
neutral
nx
asparaginexserin
nxt
asparaginexthreonin
nglycan
sequon
substitut
model
rosetta
solventexpos
posit
antigen
domain
figur
first
screen
structurebas
design
describ
assess
effect
glycoprotein
antigen
confirm
design
preserv
structur
key
epitop
disrupt
nonneutr
antigen
domain
hmab
bind
case
nglycan
design
design
clone
assess
use
elisa
panel
repres
hmab
antigen
domain
ae
figur
result
indic
mutant
maintain
approxim
wildtyp
level
bind
antibodi
truncat
vari
effect
bind
domain
e
hmab
lesser
extent
neg
affect
truncat
residu
remov
refer
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
wherea
limit
truncat
residu
remov
refer
larg
restor
bind
bnab
design
base
observ
residu
locat
within
affect
bind
likewis
design
nglycan
substitut
show
vari
effect
antigen
two
candid
structurebas
design
well
express
solubl
glycoprotein
test
thermost
bind
affin
panel
hmab
well
receptor
tabl
pairwis
combin
design
tripl
design
three
modif
also
express
test
note
previous
other
wildtyp
found
exhibit
high
thermost
tm
tabl
design
likewis
show
high
thermost
minor
reduct
tm
except
combin
tripl
lowest
measur
thermost
among
test
mutant
tm
assess
antigen
glycoprotein
design
solut
bind
affin
measur
perform
octet
use
hmab
target
antigen
domain
b
e
two
antibodi
per
domain
well
receptor
tabl
antibodi
previous
character
use
multipl
global
alanin
scan
studi
cbhauthorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
xray
structur
character
studi
affin
matur
clone
parent
antibodi
improv
affin
neutral
breadth
parent
antibodi
bind
site
map
residu
antigen
domain
b
e
thu
bind
provid
addit
assess
antigen
supersit
bind
experi
panel
show
nanomolar
bind
affin
wildtyp
larg
maintain
design
increas
bind
affin
design
domain
hmab
observ
show
design
locat
within
antigen
domain
maintain
affin
improv
engag
case
steadyst
bind
fit
interact
shown
figur
howev
effect
observ
combin
design
includ
suggest
possibl
interplay
design
site
expect
domain
hyperglycosyl
design
tripl
show
loss
bind
antigen
domain
hmab
bind
measur
shown
figur
though
observ
disrupt
bind
addit
design
show
moder
loss
bind
case
design
domain
hmab
distinct
albeit
similar
bind
determin
differenti
effect
domain
antibodi
bind
variant
reflect
like
differ
hmab
dock
footprint
measur
glycan
occup
residu
use
mass
spectroscopi
show
partial
level
glycosyl
site
combin
tabl
may
respons
incomplet
bind
ablat
test
antigen
domain
hmab
alanin
substitut
previous
found
disrupt
bind
domain
antibodi
possibl
amino
acid
substitut
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
may
respons
addit
partial
nglycosyl
effect
domain
antibodi
bind
regardless
result
suggest
least
partial
bind
disrupt
nglycan
mask
region
support
test
design
immunogen
vivo
follow
confirm
antigen
design
test
vivo
immunogen
assess
elicit
antibodi
demonstr
potenc
neutral
breadth
mice
per
group
immun
design
use
day
prime
follow
three
biweekli
boost
sera
obtain
day
two
week
final
boost
test
bind
key
conserv
epitop
e
figur
peptid
epitop
confirm
expect
monoclon
antibodi
specif
use
elisa
figur
endpoint
titer
demonstr
sera
mice
immun
design
maintain
recognit
test
epitop
intragroup
variabl
result
lack
statist
signific
differ
serum
bind
immun
group
howev
mean
titer
group
moder
lower
wildtyp
group
mutant
yield
moder
higher
serum
bind
test
epitop
notabl
design
elicit
antibodi
robustli
crossreact
wild
type
epitop
assess
differenti
bind
conform
epitop
serum
bind
competit
select
hmab
perform
figur
show
major
differ
immun
group
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
analysi
immun
serum
bind
test
bind
purifi
recombin
hcv
pseudoparticl
two
heterolog
genotyp
figur
tabl
bind
resembl
bind
appar
differ
immun
group
observ
notabl
differ
bind
hcvpp
repres
mice
versu
mice
immun
wildtyp
differ
hcvpp
bind
mice
versu
mice
highli
signific
p
kruskalw
test
confirm
differ
hcvpp
bind
immun
group
given
rel
low
level
overal
titer
hcvpp
purifi
test
elisa
bind
pool
sera
immun
mice
confirm
differ
immun
group
sera
day
well
day
correspond
three
rather
four
immun
figur
demonstr
nativelik
assembl
hcvpp
context
elisa
assay
purifi
hcvpp
show
bind
monoclon
antibodi
target
linear
conform
epitop
conform
epitop
interact
neg
control
antibodi
figur
molecular
basi
differenti
serum
reactiv
use
hcvpp
versu
purifi
recombin
elisa
unclear
particularli
given
use
immunogen
yet
result
collect
provid
evid
may
improv
target
conserv
glycoprotein
epitop
intact
hcv
virion
assess
effect
antibodi
neutral
potenc
breadth
design
test
serum
neutral
hcvpp
repres
homolog
figur
six
heterolog
isol
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
heterolog
isol
collect
diverg
substanti
sequenc
repres
neutral
phenotyp
rang
moder
highli
resist
tabl
found
previous
rel
larg
intragroup
variabl
neutral
statist
signific
differ
group
observ
howev
heterolog
isol
show
much
less
intragroup
variabl
case
design
yield
significantli
higher
neutral
wildtyp
notabl
two
resist
isol
significantli
higher
neutral
sera
wildtyp
sera
studi
appli
varieti
ration
design
approach
engin
hcv
glycoprotein
improv
antigen
immunogen
one
approach
remov
test
sever
recent
immunogen
studi
context
studi
test
mutant
residu
remov
retain
residu
conserv
truncat
previous
test
mutant
order
retain
residu
bind
determin
hmab
other
found
mutant
advantag
immunogen
standpoint
agreement
previou
immunogen
studi
test
mutant
although
immunogen
epitop
remov
recombin
glycoprotein
appear
increas
homolog
heterolog
nab
titer
latter
suggest
level
antibodi
target
conserv
nab
epitop
increas
upon
remov
base
larg
studi
engin
virus
cell
cultur
summar
recent
review
remov
associ
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
increas
nab
sensit
receptor
bind
recent
studi
indic
may
modul
viral
dynam
open
close
conform
envelop
breath
despit
import
context
virion
dynam
remov
appear
neutral
minim
effect
immunogen
recombin
envelop
glycoprotein
anoth
design
strategi
test
studi
hyperglycosyl
structurebas
addit
nglycan
sequon
mask
antigen
domain
associ
nonneutr
antibodi
concept
downmodul
immun
region
base
observ
region
highli
immunogen
may
divert
antibodi
howev
combin
lead
modest
improv
nab
titer
one
resist
isol
pvalu
compar
wildtyp
previous
use
insect
cell
express
alter
nglycan
profil
versu
mammalian
cell
express
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
other
recent
test
immunogen
glycandelet
variant
neither
case
signific
improv
homolog
heterolog
nab
respons
observ
immunogen
alter
glycan
collect
result
suggest
glycoengin
repres
challeng
possibl
less
benefici
avenu
hcv
immunogen
design
howev
report
success
other
insect
cell
express
indic
alter
glycosyl
may
help
instanc
design
substitut
gener
preferenti
adopt
bnabbound
form
portion
antigen
domain
exhibit
structur
variabl
show
greatest
level
success
regard
improv
serum
bind
homolog
heterolog
hcvpp
well
hcvpp
neutral
heterolog
hcvpp
design
lie
within
supersit
associ
mani
broadli
neutral
antibodi
biophys
character
molecular
dynam
simul
experi
other
found
region
like
quit
flexibl
provid
rational
stabil
key
residu
engag
elicit
bnab
interestingli
residu
adjac
site
design
appear
function
import
substitut
restor
viral
infect
context
hcvpp
domain
e
glycan
shift
substitut
design
strategi
util
prolin
residu
substitut
stabil
conform
viral
glycoprotein
success
hiv
env
respiratori
syncyti
viru
rsv
f
mer
coronaviru
spike
recent
novel
coronaviru
spike
data
studi
suggest
approach
also
use
context
hcv
possibl
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
studi
provid
proofofconcept
comput
structurebas
design
hcv
glycoprotein
modul
antigen
immunogen
futur
studi
design
includ
test
antigen
immunogen
context
hcv
test
immunogen
anim
model
well
confirm
impact
structur
high
resolut
xray
structur
character
addit
biophys
character
furthermor
addit
design
prolin
substitut
flexibl
neutral
face
supersit
may
confer
greater
improv
homolog
heterolog
nab
elicit
gener
use
structurebas
design
semir
librarybas
approach
use
scan
larg
set
prolin
substitut
hiv
env
studi
provid
promis
design
candid
followup
studi
underscor
valu
set
previous
determin
though
somewhat
limit
set
complex
structur
prospect
elucid
structur
complex
addit
bnab
well
character
complex
structur
facilit
futur
structurebas
design
studi
engin
optim
immunogen
effect
hcv
vaccin
prolin
substitut
design
stabil
epitop
model
previous
describ
design
cell
receptor
bind
loop
use
ramachandran
plot
server
assess
epitop
residu
backbon
conform
prolin
preprolin
conform
similar
http
zlabbuedurama
well
explicit
model
energet
effect
prolin
substitut
use
point
mutagenesi
mode
rosetta
version
nglycan
sequon
substitut
nx
nxt
model
use
rosetta
follow
model
nglycan
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
structur
use
glyprot
web
server
assess
residu
side
chain
access
surfac
area
perform
use
naccess
default
paramet
express
purif
recombin
solubl
hcv
design
perform
previous
describ
briefli
sequenc
isol
genbank
access
number
clone
character
mutant
antigen
use
elisa
perform
describ
previous
mutant
construct
plasmid
carri
code
sequenc
genbank
access
number
describ
previous
mutat
confirm
dna
sequenc
analysi
elim
biopharmaceut
inc
hayward
ca
desir
mutat
absenc
unexpect
residu
chang
fulllength
sequenc
result
plasmid
transfect
hek
cell
transient
protein
express
use
calciumphosph
method
individu
protein
express
normal
bind
hcv
hmab
linear
epitop
data
shown
mean
valu
two
experi
perform
triplic
serum
sampl
specifi
dilut
test
abil
block
bind
select
hcv
hmabsconjug
biotin
gnacaptur
glycoprotein
elisa
describ
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
interact
recombin
glycoprotein
hmab
measur
use
octet
instrument
ni
nta
biosensor
pall
fortebio
biosensor
load
purifi
wildtyp
mutant
sec
associ
sec
follow
dissoci
sec
concentr
dilut
seri
antibodi
perform
data
analysi
perform
use
octet
data
analysi
softwar
util
refer
subtract
nm
antibodi
concentr
align
baselin
interstep
correct
dissoci
step
savitzkygolay
fit
curv
global
fit
base
associ
dissoci
obtain
kd
valu
thermal
melt
curv
monomer
protein
acquir
use
microc
peaqdsc
autom
system
malvern
panalyt
purifi
monomer
protein
dialyz
pb
prior
analysi
dialysi
buffer
use
refer
experi
sampl
dilut
pb
prior
analysi
thermal
melt
probe
scan
rate
temperatur
rang
data
analys
includ
estim
melt
temperatur
perform
use
standard
protocol
includ
peaqdsc
softwar
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
iodoacetamid
room
temperatur
min
sampl
buffer
exchang
urea
tri
ph
digest
sequenti
digest
perform
use
trypsin
enzymeprotein
ratio
ww
hour
follow
chymotrypsin
enzym
protein
ww
overnight
room
temperatur
sampl
absorb
onto
seppak
column
remov
proteolyt
digest
buffer
elut
trifluoroacet
acid
tfa
buffer
concentr
dryness
centrifug
vacuum
concentr
sampl
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
antigen
solut
prime
ww
boost
immun
antigen
adjuv
ratio
provid
mcg
pcpp
dose
per
anim
absenc
aggreg
adjuv
formul
confirm
dynam
light
scatter
dl
singl
peak
zaverag
hydrodynam
diamet
nm
format
antigen
pcpp
complex
proven
asymmetr
flow
field
flow
fraction
describ
previous
schedul
vaccin
day
group
femal
mice
age
week
inject
via
intraperiton
ip
rout
prime
day
boost
day
blood
sampl
collect
prior
inject
termin
bleed
day
collect
sampl
process
serum
centrifug
store
analysi
perform
domainspecif
serum
bind
test
use
elisa
ctermin
biotinyl
peptid
aa
sequenc
niqlintngswhinst
aa
sequenc
ntgwlaglfyqhk
use
coat
concentr
recombin
protein
captur
onto
gnacoat
microtit
plate
endpoint
titer
calcul
curv
fit
graphpad
prism
softwar
endpoint
od
defin
four
time
highest
absorb
valu
day
sera
hcv
pseudoparticl
hcvpp
gener
describ
previous
cotransfect
cell
murin
leukemia
viru
mlv
gagpol
packag
vector
luciferas
report
plasmid
plasmid
express
hcv
use
lipofectamin
thermo
fisher
scientif
envelopefre
control
empti
plasmid
use
neg
control
experi
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
supernat
contain
hcvpp
harvest
h
h
posttransfect
filter
pores
membran
concentr
hcvpp
obtain
ultracentrifug
ml
filter
supernat
ml
sucros
cushion
use
sw
beckman
coulter
rotor
rpm
hour
follow
previous
report
protocol
measur
serum
bind
hcvpp
filter
hcvpp
isol
directli
coat
onto
nuncimmuno
maxisorp
thermo
scientif
microwel
overnight
microwel
wash
three
time
pb
tween
step
well
block
pierc
proteinfre
block
buffer
thermo
scientif
hour
serum
sampl
dilut
made
block
buffer
ad
microwel
incub
hour
room
temperatur
ab
detect
secondari
hrp
conjug
goat
antimous
igg
h
l
abcam
develop
tmb
substrat
solut
biorad
reaction
stop
sulfur
acid
molecular
devic
plate
reader
use
measur
absorb
nm
endpoint
titer
calcul
curv
fit
graphpad
prism
softwar
endpoint
od
defin
four
time
highest
absorb
valu
day
sera
infect
neutral
test
hcvpp
x
cell
per
well
plate
tissu
cultur
plate
corn
incub
overnight
follow
day
hcvpp
mix
appropri
amount
antibodi
incub
h
ad
cell
h
either
brightglo
promega
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ad
well
incub
min
cell
lyse
cell
lysi
buffer
promega
place
rocker
min
luciferas
activ
measur
rel
light
unit
rlu
use
either
spectramax
micropl
reader
molecular
devic
softmax
softwar
brightglo
protocol
well
individu
inject
luciferas
substrat
read
use
fluostar
omega
plate
reader
bmg
labtech
mar
softwar
infect
hcvpp
measur
presenc
mab
test
anim
sera
preimmun
anim
sera
nonspecif
igg
dilut
sampl
test
duplic
triplic
neutral
activ
report
inhibitori
dilut
valu
calcul
nonlinear
curv
fit
graphpad
prism
use
lower
upper
bound
inhibit
constraint
assist
curv
fit
pvalu
group
endpoint
titer
group
valu
calcul
use
kruskalw
oneway
analysi
varianc
anova
dunn
multipl
comparison
test
graphpad
prism
softwar
asterisk
denot
design
test
context
aa
rather
full
length
immun
sera
test
bind
hcvpp
repres
isol
use
elisa
serum
bind
test
threefold
dilut
start
valu
report
endpoint
titer
due
insuffici
sera
endpoint
titer
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
avail
one
mous
group
one
mous
group
hcvpp
hcvpp
well
two
mice
group
one
mous
group
hcvpp
pvalu
group
endpoint
titer
valu
calcul
use
kruskalw
analysi
varianc
dunn
multipl
comparison
test
signific
pvalu
control
design
group
shown
p
p
p
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
serum
dilut
perform
twofold
dilut
start
minimum
dilut
level
correspond
indic
dot
line
refer
murin
sera
low
incalcul
valu
due
low
background
level
neutral
observ
mice
hcvpp
neutral
shown
due
insuffici
sera
neutral
measur
includ
two
mice
group
one
mous
group
pvalu
group
valu
calcul
use
kruskalw
analysi
varianc
dunn
multipl
comparison
test
signific
pvalu
control
design
group
shown
p
p
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
valu
prolin
backbon
analysi
obtain
ramachandran
plot
analysi
web
server
http
zlabbuedurama
prepro
assess
correspond
preprolin
ramachandran
plot
conform
backbon
preced
residu
unfavor
pro
prepro
conform
note
gray
shade
cell
predict
bind
energi
chang
prolin
epitop
mutant
hmab
base
xray
structur
complex
pdb
code
comput
mutagenesi
rosetta
predict
destabil
valu
rosetta
energi
unit
indic
shade
cell
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
val
access
surfac
area
calcul
use
xray
structur
core
pdb
code
naccess
program
default
paramet
valu
reflect
rel
side
chain
surfac
access
normal
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
